Why Is Zimmer (ZBH) Up 5.3% Since Last Earnings Report?

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 5, 2025

Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Dec 2, 2025

Zimmer Biomet Holdings (ZBH) Faces Investor Scrutiny Amid Emerging Markets Distributor Orders Cancelation, Reduced Top-Line Revenue Forecast -- Hagens Berman

SAN FRANCISCO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- On November 5, 2025, investors in Zimmer Biomet Holdings, Inc. (NYSE: ZBH) saw the price of their shares tumble $15.63 (-15%) after the company announced its Q3 2025 financial results and revealed cancelation of emerging markets distributor orders, prompting one analyst to question management's guidance philosophy.

GlobeNewsWire • Nov 24, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zimmer Biomet Holdings, Inc. - ZBH

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Zimmer Biomet Holdings, Inc. ("Zimmer Biomet" or the "Company") (NYSE: ZBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • Nov 20, 2025

Bragar Eagel & Squire, P.C. Is Investigating Gauzy and Zimmer Biomet and Encourages Investors to Contact the Firm

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) --   Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Gauzy Ltd. (NASDAQ:GAUZ) and Zimmer Biomet Holdings, Inc. (NYSE:ZBH). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

GlobeNewsWire • Nov 20, 2025

Securities Fraud Investigation Into Zimmer Biomet Holdings, Inc. (ZBH) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Zimmer Biomet Holdings, Inc. (“Zimmer” or the “Company”) (NYSE: ZBH) investors concerning the Company's possible violations of the federal securities laws.

GlobeNewsWire • Nov 19, 2025

Zimmer Biomet Holdings, Inc. (ZBH) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Zimmer Biomet Holdings, Inc. (“Zimmer” or the “Company”) (NYSE: ZBH) investors concerning the Company's possible violations of federal securities laws.

GlobeNewsWire • Nov 19, 2025

Securities Fraud Investigation Into Zimmer Biomet Holdings, Inc. (ZBH) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Zimmer Biomet Holdings, Inc. (“Zimmer” or the “Company”) (NYSE: ZBH) on behalf of investors concerning the Company's possible violations of federal securities laws.

GlobeNewsWire • Nov 19, 2025

Zimmer Biomet Holdings, Inc. (ZBH) Presents at Jefferies London Healthcare Conference 2025 Transcript

Zimmer Biomet Holdings, Inc. ( ZBH ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:00 AM EST Company Participants Ivan Tornos - President, CEO & Chairman of the Board Suketu Upadhyay - CFO and Executive VP of Finance, Operations & Supply Chain Conference Call Participants Matthew Taylor - Jefferies LLC, Research Division Presentation Matthew Taylor Jefferies LLC, Research Division All right. Great. Thanks for joining us for our next session here at the Jefferies Healthcare Conference.

Seeking Alpha • Nov 18, 2025

Could Zimmer Biomet Stock Be Your Next Buy?

Zimmer Biomet (ZBH) could be a strong choice for your investment portfolio, due to its high cash yield, solid fundamentals, and discounted valuation. Companies like this have the capacity to leverage cash for additional revenue growth or to reward their shareholders through dividends or buybacks.

Forbes • Nov 17, 2025